Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Björn Engelbrekt Wahlin"'
Autor:
Henna‐Riikka Junlén, Kristina Sonnevi, Ola Lindén, Mats Hellström, Mariana Villegas Scivetti, Mikael Olsson, Ida Tufvesson, Ann‐Sofie Johansson, Björn Engelbrekt Wahlin
Publikováno v:
eJHaem, Vol 4, Iss 3, Pp 647-655 (2023)
Abstract The treatment of splenic marginal zone lymphoma is debated: splenectomy (the old standard‐of‐care) is better than chemotherapy but maybe not better than rituximab‐containing treatment. We examined all 358 patients diagnosed with spleni
Externí odkaz:
https://doaj.org/article/14ba6b16f13442de8900e031480884d7
Autor:
Riccardo Pecori, Weicheng Ren, Mohammad Pirmoradian, Xianhuo Wang, Dongbing Liu, Mattias Berglund, Wei Li, Rafail Nikolaos Tasakis, Salvatore Di Giorgio, Xiaofei Ye, Xiaobo Li, Annette Arnold, Sandra Wüst, Martin Schneider, Karthika-Devi Selvasaravanan, Yvonne Fuell, Thorsten Stafforst, Rose-Marie Amini, Kristina Sonnevi, Gunilla Enblad, Birgitta Sander, Björn Engelbrekt Wahlin, Kui Wu, Huilai Zhang, Dominic Helm, Marco Binder, F. Nina Papavasiliou, Qiang Pan-Hammarström
Publikováno v:
iScience, Vol 26, Iss 6, Pp 106864- (2023)
Summary: Diffuse large B cell lymphoma (DLBCL) is one of the most common types of aggressive lymphoid malignancies. Here, we explore the contribution of RNA editing to DLBCL pathogenesis. We observed that DNA mutations and RNA editing events are ofte
Externí odkaz:
https://doaj.org/article/06e7c6d062c04ab1819616c3c1a37e1a
Autor:
Caroline E. Weibull, Tove Wästerlid, Björn Engelbrekt Wahlin, Per-Ola Andersson, Sara Ekberg, Sandra Lockmer, Gunilla Enblad, Michael J. Crowther, Eva Kimby, Karin E. Smedby
Publikováno v:
HemaSphere, Vol 7, Iss 3, p e838 (2023)
In follicular lymphoma (FL), progression of disease ≤24 months (POD24) has emerged as an important prognostic marker for overall survival (OS). We aimed to investigate survival more broadly by timing of progression and treatment in a national popul
Externí odkaz:
https://doaj.org/article/39d5fc75e5ef43388f6aaf43bf4eb9e6
Autor:
Kristina Sonnevi, Maria Ljungqvist, Jóel Kristinn Jóelsson, Sara Harrysson, Tove Wästerlid, Per Bernell, Björn Engelbrekt Wahlin
Publikováno v:
eJHaem, Vol 2, Iss 4, Pp 774-784 (2021)
Abstract Patients with high‐risk aggressive B‐cell lymphoma exhibit poor survival after R‐CHOP. More intensive regimens yield higher rates of remission but also of complication. We investigated all 401 patients
Externí odkaz:
https://doaj.org/article/5185da9e7f6e45189ee1703f58593a70
Autor:
Björn Engelbrekt Wahlin, Ninja Övergaard, Stefan Peterson, Evangelos Digkas, Ingrid Glimelius, Ingemar Lagerlöf, Ann‐Sofie Johansson, Marzia Palma, Lotta Hansson, Johan Linderoth, Christina Goldkuhl, Daniel Molin
Publikováno v:
eJHaem, Vol 2, Iss 3, Pp 400-412 (2021)
Abstract Treatment for patients > 60 years with classical Hodgkin lymphoma (cHL) is problematic; there is no gold standard, and outcome is poor. Using the Swedish Lymphoma Registry, we analysed all Swedish patients diagnosed with cHL between 2000 and
Externí odkaz:
https://doaj.org/article/63302eca98bd48feaf9e6ae6bdbac5ba
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Chimeric antigen-receptor T-cell and bispecific antibody therapies will likely necessitate a reconsideration of the role of autologous stem-cell transplantation (ASCT) in lymphoma. Patients who are likely to profit from ASCT need
Externí odkaz:
https://doaj.org/article/9fc255f64318455fbb3b11a295151564
Autor:
Mattias Carlsten, Martin Jädersten, Anna Hellström, Karin Littmann, Christopher M. Melén, Henna Riikka Junlén, Kristina Sonnevi, Per Ljungman, Bo Björkstrand, Björn Engelbrekt Wahlin
Publikováno v:
Experimental Hematology & Oncology, Vol 8, Iss 1, Pp 1-12 (2019)
Abstract Background Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality. Methods All 433 lymphoma patients who underwent ASCT for lymphoma at Karolinska Huddinge 1994–2016 were investigated, incl
Externí odkaz:
https://doaj.org/article/6151d85a68224b20851a8ffbd15b5daa
Autor:
Monika Enqvist, Benedikt Jacobs, Henna R. Junlén, Marie Schaffer, Christopher M. Melén, Danielle Friberg, Björn Engelbrekt Wahlin, Karl-Johan Malmberg
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Monotherapy with the anti-CD20 monoclonal antibody rituximab can induce complete responses (CR) in patients with follicular lymphoma (FL). Resting FcRγIII+ (CD16+) natural killer (NK) cells respond strongly to rituximab-coated target cells in vitro.
Externí odkaz:
https://doaj.org/article/4854c61614b547e18686310ba67d7de1
Autor:
Christopher M. Melén, Magali Merrien, Agata M. Wasik, Birgitta Sander, Björn Engelbrekt Wahlin, Georgios Panagiotis, Olof Beck
Publikováno v:
Cannabis and Cannabinoid Research.
Autor:
Karl-Johan Malmberg, Hans-Gustaf Ljunggren, Eva Hellström-Lindberg, Per Ljungman, Lotta Hansson, Marzia Palma, Björn Engelbrekt Wahlin, Pontus Blomberg, Kristina Wikström, Emma Watz, Marie Schaffer, Monika Klimkowska, Jeffrey S. Miller, Sarah Cooley, Mohsen Karimi, Trevor Clancy, Lisa L. Liu, Ebba Sohlberg, Mattias Carlsten, Andreas T. Björklund
Supplementary Figures and Tables Supplemental Figure 1. Persistence of donor NK cells in vivo. (A) Frequency of patients with detectable donor NK cells in peripheral blood (PB) at day (d)7 and/or 14 after NK cell infusion in nonresponders (NR) and re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d179003f025392a7c5d482cd8d16578
https://doi.org/10.1158/1078-0432.22469262
https://doi.org/10.1158/1078-0432.22469262